Worries Mount Over Cancer Risks in Bluebird Bio's Gene Therapy
7 Children Given Bluebird's Skysona Developed Blood Cancer: Study
Bluebird Bio's Skysona Led to Seven Cases of Blood Cancer in Gene Therapy Trials
J.P. Morgan Maintains Bluebird Bio(BLUE.US) With Hold Rating
Top 10 Most Shorted Stocks on Wall Street
Bluebird Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Bluebird Bio Announces Completion of Its Q2 2024 Form 10-Q Filing
bluebird bio | 10-Q: Q2 2024 Earnings Report
Bluebird Bio's Restructuring Efforts and Financial Outlook: A Cautious Hold Rating
Pfizer Withdraws Sickle Cell Drug Oxbryta Over Safety Concerns
Bluebird Bio Is Maintained at Equal-Weight by Wells Fargo
Bluebird Bio Analyst Ratings
Wells Fargo Maintains Bluebird Bio(BLUE.US) With Hold Rating, Cuts Target Price to $2
Express News | Bluebird bio Inc : Wells Fargo Cuts Target Price to $2 From $3
Maintaining Hold on Bluebird Bio: Balancing LYFGENIA's Promise Against Financial and Operational Hurdles
Barclays Maintains Bluebird Bio(BLUE.US) With Buy Rating, Maintains Target Price $4
Barclays analyst Gena Wang maintains $bluebird bio(BLUE.US)$ with a buy rating, and maintains the target price at $4.According to TipRanks data, the analyst has a success rate of 44.3% and a total
Analysts Are Bullish on Top Healthcare Stocks: Bluebird Bio (BLUE), Immunic (IMUX)
William Blair Maintains Bluebird Bio(BLUE.US) With Hold Rating
William Blair analyst Sami Corwin maintains $bluebird bio(BLUE.US)$ with a hold rating.According to TipRanks data, the analyst has a success rate of 47.1% and a total average return of 2.7% over the
William Blair Reaffirms Their Hold Rating on Bluebird Bio (BLUE)
Sector Update: Health Care Stocks Steady Pre-Bell Tuesday